Director at Protagonist (PTGX) exercises 14,299 stock options on 01/09/2026

Rhea-AI Filing Summary

Protagonist Therapeutics director Harold E. Selick reported exercising a stock option on 01/09/2026, converting 14,299 stock options with an exercise price of $4.21 into 14,299 shares of common stock. The transaction is coded “M,” indicating an option exercise.

Following this transaction, Selick directly beneficially owns 60,845 shares of Protagonist Therapeutics common stock. The filing notes that the stock options exercised were fully vested and that no derivative securities of this option grant remain outstanding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SELICK HAROLD E

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		M		14,299	A	$4.21	60,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.21	01/09/2026		M			14,299	(1)	04/29/2026	Common Stock	14,299	$0.00	0	D

Explanation of Responses:

1. These stock options are fully vested.

	/s/ Matthew Gosling, Attorney-in-Fact for Harold E. Selick	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Protagonist Therapeutics (PTGX) report for Harold E. Selick?

Harold E. Selick, a director of Protagonist Therapeutics, reported the exercise of 14,299 stock options on 01/09/2026, receiving 14,299 shares of common stock in return.

At what price were Harold E. Selick’s Protagonist Therapeutics options exercised?

Selick exercised a stock option (right to buy) covering 14,299 shares of Protagonist Therapeutics common stock at an exercise price of $4.21 per share.

How many Protagonist Therapeutics shares does Harold E. Selick own after this Form 4 transaction?

After the reported option exercise, Harold E. Selick beneficially owns 60,845 shares of Protagonist Therapeutics common stock, all held in direct ownership form.

What happened to the stock options Harold E. Selick exercised at Protagonist Therapeutics?

The Form 4 shows 14,299 stock options with a $4.21 exercise price were exercised (code M), leaving 0 derivative securities of that option position beneficially owned after the transaction.

Were Harold E. Selick’s Protagonist Therapeutics options vested at the time of exercise?

Yes. A footnote states that these stock options are fully vested, confirming that all 14,299 options exercised on 01/09/2026 were already vested.

What role does Harold E. Selick hold at Protagonist Therapeutics (PTGX)?

In this Form 4, Harold E. Selick is identified as a director of Protagonist Therapeutics and is not listed as an officer or 10% owner.